Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration

Sponsor

Chulalongkorn University (Other)

Overall Status

Completed

CT.gov ID

NCT02576873

Collaborator

(none)

Enrollment

Location

Duration (Months)

2.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in King Chulalongkorn Memorial Hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

Condition or Disease	Intervention/Treatment	Phase
End-stage Renal Disease	Other: Hemodiafiltration

Detailed Description

Growing evidences suggested the superiority of high-efficiency hemodiafiltration (HDF) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. However, the long-term, upto 10 years, outcome still limited. This retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, King Chulalongkorn Memorial Hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Study Design

Study Type:

Observational

Actual Enrollment :

66 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Long-term Outcome of End-stage Renal Disease Patients Treated With High-efficiency Hemodiafiltration: a Historical Cohort of a Single-center in South East Asia

Study Start Date :

Mar 1, 2014

Actual Primary Completion Date :

Oct 1, 2015

Actual Study Completion Date :

Mar 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Hemodiafiltration End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months	Other: Hemodiafiltration Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies

Arm

Intervention/Treatment

Hemodiafiltration

End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months

Other: Hemodiafiltration

Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies

Outcome Measures

Primary Outcome Measures

Survival rate [10 years]
The Kaplan-Meier survival curve and mean survival time will be demonstrated for primary outcome.

Secondary Outcome Measures

Comparison of survival differences between patients who start renal replacement therapy with HDF and who switched from hemodialysis as well as between diabetic and non-diabetic patient. [10 years]
Survival differences between groups will be evaluated with the Kaplan-Meier method and compared using the log-rank test. The comparative groups include: Patient who start renal replacement therapy with HDF (incident cases) vs. who switched from hemodialysis (prevalence cases) Diabetic vs. Non-diabetic patients
Factors that associated with all-cause mortality [10 years]
univariate and multivariate analysis the factors that might affected the long-term outcomes. The factors include dialytic parameters (spKt/Vurea, TAC urea), nutritional parameters (nPNA, albumin), inflammatory parameter (hsCRP), and biochemical parameters (BUN, Cr, Ca, Phosphate, iPTH, beta2-microglobulin, Hb, Ferritin, Transferrin saturation, Cholesterol, Triglyceride, HDL, and LDL)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Aged 18 years or more
Be diagnosed end-stage renal disease for more than one year
Have been regularly received long-term hemodiafiltration for more than 6 months.